Viking's MASH drug scored where Madrigal's didn't, but shares fall on lack of direction

Viking Therapeutics is pulling up some extra long boats full of reasons the metabolic dysfunction-associated steatohepatitis (MASH) drug VK2809 could be a winner, but executives were mum on exactly what the med’s future will be given the competitive landscape.